Business UpdateJul 14, 2026, 03:51 PM
AngioDynamics Completes Key Divestments, Gains NanoKnife Approvals
AI Summary
AngioDynamics Inc. reported significant strategic changes, including the divestment of its dialysis and BioSentry businesses in June 2023, and its PICC and Midline businesses in February 2024. The company also discontinued its RadioFrequency Ablation and Syntrax product lines. Positively, its NanoKnife System received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024 and BSI approval for the MDR CE mark for expanded indications in February 2026. As of November 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately $436.3 million.
Key Highlights
- Sold dialysis and BioSentry businesses to Merit Medical Systems, Inc. on June 8, 2023.
- Sold PICC and Midline businesses, including C3 Wave asset, to Spectrum Vascular on February 15, 2024.
- Discontinued RadioFrequency Ablation and Syntrax product lines as of February 29, 2024.
- NanoKnife System received expanded FDA 510(k) clearance for prostate tissue ablation in December 2024.
- NanoKnife System received BSI approval for MDR CE mark for expanded indications in February 2026.
- Aggregate market value of common stock held by non-affiliates was approximately $436,293,219 as of November 30, 2025.
- 41,332,389 shares of common stock outstanding as of July 10, 2026.
Price Impact
More from ANGO